Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Adaptimmune Therapeutics plc (473A.F)

0.2180
+0.0290
+(15.34%)
At close: April 25 at 3:49:30 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
178,032
178,032
60,281
27,148
6,149
Cost of Revenue
70
70
--
--
--
Gross Profit
177,962
177,962
60,281
27,148
--
Operating Expense
230,371
230,371
198,319
191,113
168,395
Operating Income
-52,409
-52,409
-138,038
-163,965
-162,246
Net Non Operating Interest Income Expense
3,248
3,248
5,964
1,542
1,095
Other Income Expense
-18,077
-18,077
19,539
-536
3,852
Pretax Income
-67,238
-67,238
-112,535
-162,959
-157,299
Tax Provision
3,576
3,576
1,336
2,497
791
Net Income Common Stockholders
-70,814
-70,814
-113,871
-165,456
-158,090
Diluted NI Available to Com Stockholders
-70,814
-70,814
-113,871
-165,456
-158,090
Basic EPS
-0.30
-0.30
-0.54
-1.02
-1.02
Diluted EPS
-0.30
-0.30
-0.54
-1.02
-1.02
Basic Average Shares
252,301.8090
252,301.8090
201,073.4960
161,207.0670
155,805.5030
Diluted Average Shares
252,301.8090
252,301.8090
201,073.4960
161,207.0670
155,805.5030
Total Operating Income as Reported
-68,760
-68,760
-139,741
-163,965
-162,246
Total Expenses
230,441
230,441
198,319
191,113
168,395
Net Income from Continuing & Discontinued Operation
-70,814
-70,814
-113,871
-165,456
-158,090
Normalized Income
-58,550.7500
-58,550.7500
-130,351.2600
-165,456
-158,090
Interest Income
6,596
6,596
5,964
1,542
1,095
Interest Expense
3,348
3,348
--
--
--
Net Interest Income
3,248
3,248
5,964
1,542
1,095
EBIT
-63,890
-63,890
-112,535
-162,959
-162,246
EBITDA
-52,665
-52,665
-102,695
-156,884
-155,679
Reconciled Cost of Revenue
70
70
--
--
--
Reconciled Depreciation
11,225
11,225
9,840
6,075
6,567
Net Income from Continuing Operation Net Minority Interest
-70,814
-70,814
-113,871
-165,456
-158,090
Total Unusual Items Excluding Goodwill
-16,351
-16,351
20,346
--
--
Total Unusual Items
-16,351
-16,351
20,346
--
--
Normalized EBITDA
-36,314
-36,314
-123,041
-156,884
-155,679
Tax Rate for Calcs
0.0003
0.0003
0.0002
0.0002
0.0002
Tax Effect of Unusual Items
-4,087.7500
-4,087.7500
3,865.7400
--
--
12/31/2021 - 6/1/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2105.HK Laekna, Inc.
13.660
-6.18%
 
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
293.800
-4.67%
 
9969.HK InnoCare Pharma Limited
10.140
-3.61%
 
SION Sionna Therapeutics, Inc.
12.14
-3.65%
 
1672.HK ASCLETIS-B
6.280
-6.69%
 
ALXO ALX Oncology Holdings Inc.
0.5417
-9.87%
 
EWTX Edgewise Therapeutics, Inc.
14.84
-3.64%
 
9926.HK Akeso, Inc.
98.900
-1.10%
 
CYTK Cytokinetics, Incorporated
40.43
+0.25%
 
DYN Dyne Therapeutics, Inc.
11.06
-0.45%